Fibrous dysplasia of bone/McCune-Albright syndrome (Polyostotic FD/MAS; OMIM#174800) is a crippling skeletal disease caused by gain-of-function mutations of Gsα. Enhanced bone resorption is a recurrent histological feature of FD and a major cause of fragility of affected bones. Previous work suggests that increased bone resorption in FD is driven by RANKL and some studies have shown that the anti-RANKL monoclonal antibody, denosumab, reduces bone turnover and bone pain in FD patients. However, the effect of RANKL inhibition on the histopathology of FD and its impact on the natural history of the disease remain to be assessed. In this study, we treated the EF1α-GsαR201C mice, which develop an FD-like phenotype, with an anti-mouse RANKL monoclonal antibody. We found that the treatment induced marked radiographic and microscopic changes at affected skeletal sites in 2-month-old mice. The involved skeletal segments became sclerotic due to the deposition of new, highly mineralized bone within developing FD lesions and showed a higher mechanical resistance compared to affected segments from untreated transgenic mice. Similar changes were also detected in older mice with a full-blown skeletal phenotype. The administration of anti-mouse RANKL antibody arrested the growth of established lesions and, in young mice, prevented the appearance of new ones. However, after drug withdrawal, the newly formed bone was remodelled into FD tissue and the disease progression resumed in young mice. Taken together, our results show that the anti-RANKL antibody significantly affected the bone pathology and natural history of FD in the mouse. Pending further work on the prevention and management of relapse after treatment discontinuation, our preclinical study suggests that RANKL inhibition may be an effective therapeutic option for FD patients.

RANKL inhibition in fibrous dysplasia of bone: a preclinical study in a mouse model of the human disease / Palmisano, B.; Spica, E.; Remoli, C.; Labella, R.; Di Filippo, A.; Donsante, S.; Bini, F.; Raimondo, D.; Marinozzi, F.; Boyde, A.; Robey, P.; Corsi, A.; Riminucci, M.. - In: JOURNAL OF BONE AND MINERAL RESEARCH. - ISSN 0884-0431. - 34:12(2019), pp. 2171-2182. [10.1002/jbmr.3828]

RANKL inhibition in fibrous dysplasia of bone: a preclinical study in a mouse model of the human disease

Palmisano B.
Primo
;
Spica E.;Remoli C.;Labella R.;Donsante S.;Bini F.;Raimondo D.;Marinozzi F.;Corsi A.;Riminucci M.
2019

Abstract

Fibrous dysplasia of bone/McCune-Albright syndrome (Polyostotic FD/MAS; OMIM#174800) is a crippling skeletal disease caused by gain-of-function mutations of Gsα. Enhanced bone resorption is a recurrent histological feature of FD and a major cause of fragility of affected bones. Previous work suggests that increased bone resorption in FD is driven by RANKL and some studies have shown that the anti-RANKL monoclonal antibody, denosumab, reduces bone turnover and bone pain in FD patients. However, the effect of RANKL inhibition on the histopathology of FD and its impact on the natural history of the disease remain to be assessed. In this study, we treated the EF1α-GsαR201C mice, which develop an FD-like phenotype, with an anti-mouse RANKL monoclonal antibody. We found that the treatment induced marked radiographic and microscopic changes at affected skeletal sites in 2-month-old mice. The involved skeletal segments became sclerotic due to the deposition of new, highly mineralized bone within developing FD lesions and showed a higher mechanical resistance compared to affected segments from untreated transgenic mice. Similar changes were also detected in older mice with a full-blown skeletal phenotype. The administration of anti-mouse RANKL antibody arrested the growth of established lesions and, in young mice, prevented the appearance of new ones. However, after drug withdrawal, the newly formed bone was remodelled into FD tissue and the disease progression resumed in young mice. Taken together, our results show that the anti-RANKL antibody significantly affected the bone pathology and natural history of FD in the mouse. Pending further work on the prevention and management of relapse after treatment discontinuation, our preclinical study suggests that RANKL inhibition may be an effective therapeutic option for FD patients.
2019
bone remodelling; denosumab; fibrous dysplasia; RANKL; GSα
01 Pubblicazione su rivista::01a Articolo in rivista
RANKL inhibition in fibrous dysplasia of bone: a preclinical study in a mouse model of the human disease / Palmisano, B.; Spica, E.; Remoli, C.; Labella, R.; Di Filippo, A.; Donsante, S.; Bini, F.; Raimondo, D.; Marinozzi, F.; Boyde, A.; Robey, P.; Corsi, A.; Riminucci, M.. - In: JOURNAL OF BONE AND MINERAL RESEARCH. - ISSN 0884-0431. - 34:12(2019), pp. 2171-2182. [10.1002/jbmr.3828]
File allegati a questo prodotto
File Dimensione Formato  
Palmisano_RANKL_2019.pdf

accesso aperto

Note: https://asbmr.onlinelibrary.wiley.com/doi/full/10.1002/jbmr.3828
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 907.25 kB
Formato Adobe PDF
907.25 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1381203
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 32
social impact